D
David B. Agus
Researcher at University of Southern California
Publications - 152
Citations - 13587
David B. Agus is an academic researcher from University of Southern California. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 51, co-authored 150 publications receiving 11949 citations. Previous affiliations of David B. Agus include Johns Hopkins University & Harvard University.
Papers
More filters
Journal ArticleDOI
A cross-platform toolkit for mass spectrometry and proteomics
Matthew C. Chambers,Brendan MacLean,Robert Burke,Dario Amodei,Daniel Ruderman,Steffen Neumann,Laurent Gatto,Bernd Fischer,Brian S. Pratt,Jarrett D. Egertson,Katherine Hoff,Darren Kessner,Natalie Tasman,Nicholas J. Shulman,Barbara Frewen,Tahmina A Baker,Mi-Youn Brusniak,Christopher Paulse,David M. Creasy,Lisa Flashner,Kian Kani,Chris Moulding,Sean L. Seymour,Lydia M. Nuwaysir,Brent Lefebvre,Frank E. Kuhlmann,Joe Roark,Paape Rainer,Suckau Detlev,Tina Hemenway,Andreas Huhmer,James I. Langridge,Brian Connolly,Trey Chadick,Krisztina Holly,Josh Eckels,Eric W. Deutsch,Robert L. Moritz,Jonathan E. Katz,David B. Agus,Michael J. MacCoss,David L. Tabb,Parag Mallick,Parag Mallick +43 more
TL;DR: The ProteoWizard Toolkit is developed, a robust set of open-source, software libraries and applications designed to facilitate proteomics research that implements the first-ever, non-commercial, unified data access interface for proteomics, bridging field-standard open formats and all common vendor formats.
Journal ArticleDOI
ProteoWizard: open source software for rapid proteomics tools development
TL;DR: The ProteoWizard project provides a modular and extensible set of open-source, cross-platform tools and libraries that perform proteomics data analyses and enable rapid tool creation by providing a robust, pluggable development framework that simplifies and unifies data file access.
Journal ArticleDOI
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
David B. Agus,Robert W. Akita,William D. Fox,Gail D. Lewis,Brian Higgins,Paul I. Pisacane,Julie A. Lofgren,Charles A. Tindell,Douglas P Evans,Krista Maiese,Howard I. Scher,Mark X. Sliwkowski +11 more
TL;DR: It is demonstrated that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment, which sterically hinders ErbB2's recruitment intoErbB ligand complexes.
Journal Article
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Lisa M. Butler,David B. Agus,Howard I. Scher,Brian Higgins,Adam Rose,Carlos Cordon-Cardo,Howard T. Thaler,Richard A. Rifkind,Paul A. Marks,Victoria M. Richon +9 more
TL;DR: The results suggest that hydroxamic acid-based hybrid polar compounds inhibit prostate cancer cell growth and may be useful, relatively nontoxic agents for the treatment of prostate carcinoma.
Journal Article
17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts
David B. Solit,Fuzhong F. Zheng,Maria Drobnjak,Pamela N. Munster,Brian Higgins,David Verbel,Glenn Heller,William P. Tong,Carlos Cordon-Cardo,David B. Agus,Howard I. Scher,Neal Rosen +11 more
TL;DR: It is demonstrated that, at a tolerable dose, inhibition of Hsp90 function by 17-AAG results in a marked reduction in HER2, AR, and Akt expression and inhibition of prostate tumor growth in mice, suggesting that this drug may represent a new strategy for the treatment of prostate cancer.